Transport
Children's Hospital & Medical Center
Children's Hospital & Medical Center was paid $89.79M by Medicaid between Jan 2018 and Dec 2024, across 417 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoCHILDREN'S HOSPITAL & MEDICAL CENTER
OMAHA, NE 68114
OMAHA, NE 68114
33aNPI1346297843assigned 05/28/2006
33bProvider typeAmbulance
28Total paid$89.79M
24GClaims1,087,441
24DCodes billed417
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Nebraska
Rank by total paid#1 of 8
Median peer was paid$103K
This provider vs. median868×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 174,056 | $13.69M | |
| 2019 | 159,708 | $12.97M | |
| 2020 | 121,560 | $10.76M | |
| 2021 | 228,263 | $17.72M | |
| 2022 | 229,161 | $18.29M | |
| 2023 | 122,044 | $10.83M | |
| 2024incomplete | 52,649 | $5.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 42,366 | 41,097 | $9.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.9% | 28,946 | 28,084 | $7.10M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.2% | 1,474 | 1,427 | $3.78M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.8% | 4,129 | 4,016 | $3.40M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 3.5% | 4,351 | 4,254 | $3.15M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.0% | 1,774 | 1,737 | $2.65M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.9% | 1,190 | 1,147 | $2.61M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.7% | 2,519 | 2,243 | $2.45M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 4,702 | 3,348 | $2.24M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.2% | 12,998 | 5,478 | $1.98M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.2% | 1,375 | 1,369 | $1.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 10,644 | 10,103 | $1.86M |
405 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 13,315 | $1.74M |
| 95782 | 1.8% | 960 | $1.63M | |
| G0378 | Hospital observation service, per hour | 1.7% | 6,448 | $1.54M |
| 76770 | 1.6% | 4,319 | $1.43M | |
| 92587 | 1.6% | 6,186 | $1.42M | |
| A0427 | Emergency ambulance ride, advanced life support | 1.4% | 4,183 | $1.24M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 9,672 | $1.22M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.3% | 4,530 | $1.17M |
| 93325 | 1.3% | 4,949 | $1.12M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 7,191 | $984K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 9,385 | $968K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,398 | $896K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,397 | $886K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,965 | $877K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 19,735 | $771K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 253 | $768K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,535 | $754K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,112 | $748K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,300 | $740K |
| A0425 | Ground mileage, per statute mile | <1% | 6,748 | $726K |
| J3490 | Unclassified drugs | <1% | 88,812 | $685K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,622 | $659K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,911 | $634K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,111 | $608K |
| 01922 | <1% | 2,686 | $595K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 229 | $553K |
| V2020 | Frames, purchases | <1% | 15,310 | $549K |
| 83655 | <1% | 22,173 | $501K | |
| 96415 | <1% | 990 | $461K | |
| 94375 | <1% | 3,779 | $452K | |
| 95819 | <1% | 1,077 | $426K | |
| 87631 | <1% | 2,538 | $415K | |
| 92567 | <1% | 7,308 | $414K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,154 | $409K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,394 | $385K |
| A0434 | Specialty care transport (sct) | <1% | 990 | $372K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 749 | $350K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 535 | $328K |
| 97165 | <1% | 2,210 | $323K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,203 | $315K |
| 80053 | Comprehensive metabolic panel | <1% | 25,868 | $307K |
| 74018 | <1% | 3,807 | $303K | |
| 12011 | <1% | 825 | $295K | |
| 87507 | <1% | 1,066 | $290K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,300 | $279K |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 8,496 | $277K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 822 | $268K |
| 94060 | <1% | 1,738 | $266K | |
| 97161 | <1% | 2,534 | $262K | |
| 73590 | <1% | 3,252 | $250K | |
| 93320 | <1% | 4,187 | $242K | |
| 84439 | <1% | 12,802 | $238K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 4,436 | $232K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 3,029 | $223K |
| V2784 | Lens, polycarbonate or equal, any index, per lens | <1% | 11,334 | $221K |
| 92015 | Determination of refractive state | <1% | 14,520 | $219K |
| 95816 | <1% | 556 | $212K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,086 | $209K |
| 73090 | <1% | 2,548 | $203K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,885 | $198K |
| 73552 | <1% | 2,302 | $196K | |
| 93975 | <1% | 690 | $193K | |
| 74019 | <1% | 3,322 | $192K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,729 | $190K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 11,372 | $186K |
| V2100 | Sphere, single vision, plano to plus or minus 4.00, per lens | <1% | 4,971 | $181K |
| 74230 | <1% | 860 | $181K | |
| 73100 | <1% | 1,898 | $178K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,166 | $176K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,338 | $169K |
| 73610 | <1% | 1,788 | $158K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,271 | $156K |
| 76536 | <1% | 573 | $154K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,022 | $145K |
| 72082 | <1% | 1,545 | $141K | |
| 73521 | <1% | 1,387 | $140K | |
| 73630 | <1% | 1,670 | $139K | |
| 92611 | <1% | 777 | $136K | |
| 73070 | <1% | 1,465 | $135K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 259 | $130K |
| 77080 | <1% | 802 | $128K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,202 | $124K |
| 93225 | <1% | 985 | $121K | |
| 77072 | <1% | 1,248 | $120K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,108 | $118K |
| 93226 | <1% | 1,064 | $117K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,827 | $116K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 266 | $116K |
| 12001 | <1% | 291 | $113K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,424 | $111K |
| 72081 | <1% | 1,319 | $110K | |
| 92002 | <1% | 2,930 | $109K | |
| 80050 | General health panel | <1% | 4,329 | $107K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 26,070 | $107K |
| J2704 | Injection, propofol, 10 mg | <1% | 9,384 | $106K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,682 | $106K |
| 92579 | <1% | 2,156 | $104K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 960 | $101K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,106 | $99K |
| 92610 | <1% | 816 | $98K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,945 | $98K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,508 | $97K |
| 97162 | <1% | 824 | $97K | |
| 36430 | <1% | 465 | $90K | |
| 31622 | <1% | 43 | $89K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 300 | $88K |
| 73080 | <1% | 994 | $87K | |
| 80061 | Lipid panel | <1% | 6,564 | $85K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,681 | $83K |
| 73140 | <1% | 1,167 | $82K | |
| V2104 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, 2.12 to 4.00d cylinder, per lens | <1% | 2,546 | $80K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,082 | $79K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,405 | $79K |
| 92526 | <1% | 710 | $79K | |
| 51701 | <1% | 2,935 | $78K | |
| 86140 | <1% | 9,515 | $75K | |
| 82728 | <1% | 4,722 | $73K | |
| 83516 | <1% | 4,525 | $72K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,393 | $71K |
| 0099U | <1% | 370 | $69K | |
| 92555 | <1% | 951 | $68K | |
| 72170 | <1% | 906 | $68K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,110 | $67K |
| 92523 | <1% | 690 | $66K | |
| 82784 | <1% | 4,587 | $66K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,512 | $61K |
| 74240 | <1% | 294 | $61K | |
| 76870 | <1% | 361 | $60K | |
| 73562 | <1% | 747 | $59K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 168 | $59K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,213 | $59K |
| 94760 | <1% | 4,004 | $59K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,173 | $58K |
| 95812 | <1% | 73 | $58K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,488 | $57K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,593 | $56K |
| 76885 | <1% | 194 | $56K | |
| 92552 | <1% | 364 | $55K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,058 | $54K |
| 90378 | <1% | 236 | $53K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,001 | $49K |
| 76376 | <1% | 198 | $48K | |
| 94761 | <1% | 3,351 | $48K | |
| 86003 | <1% | 2,045 | $47K | |
| 96409 | <1% | 697 | $46K | |
| 83970 | <1% | 850 | $46K | |
| 73130 | <1% | 627 | $46K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 364 | $46K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 13 | $45K |
| 87581 | <1% | 1,057 | $44K | |
| 87486 | <1% | 1,056 | $44K | |
| 0097U | <1% | 215 | $43K | |
| 81001 | <1% | 14,297 | $43K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,632 | $43K |
| 85007 | <1% | 6,432 | $41K | |
| 80069 | <1% | 2,608 | $40K | |
| 82247 | <1% | 5,059 | $40K | |
| 84305 | <1% | 1,515 | $39K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,726 | $39K |
| 87077 | <1% | 3,775 | $39K | |
| 85027 | <1% | 6,446 | $34K | |
| 83550 | <1% | 3,372 | $34K | |
| A0200 | Non-emergency transportation: ancillary: lodging escort | <1% | 1,382 | $34K |
| 96367 | <1% | 153 | $33K | |
| 85652 | <1% | 6,126 | $33K | |
| 82803 | <1% | 2,576 | $32K | |
| 70360 | <1% | 392 | $32K | |
| 82570 | <1% | 4,691 | $31K | |
| 87081 | <1% | 3,378 | $31K | |
| 73560 | <1% | 422 | $31K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 895 | $31K |
| 87070 | <1% | 2,959 | $30K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 73 | $30K |
| 96450 | <1% | 29 | $28K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 32 | $28K |
| 87186 | <1% | 3,680 | $28K | |
| 86900 | <1% | 1,666 | $27K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,180 | $27K |
| 74181 | <1% | 40 | $25K | |
| 83540 | <1% | 3,513 | $24K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,596 | $24K |
| 73000 | <1% | 301 | $23K | |
| 51600 | <1% | 48 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 643 | $22K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,095 | $22K |
| 88342 | <1% | 323 | $22K | |
| 90686 | <1% | 701 | $22K | |
| 96376 | <1% | 1,483 | $21K | |
| 42830 | <1% | 25 | $21K | |
| 36591 | <1% | 518 | $21K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 163 | $21K |
| 83735 | <1% | 3,936 | $21K | |
| 83880 | <1% | 783 | $21K | |
| 36416 | <1% | 7,212 | $21K | |
| A0210 | Non-emergency transportation: ancillary: meals-escort | <1% | 2,222 | $21K |
| J9370 | Vincristine sulfate, 1 mg | <1% | 306 | $20K |
| 36000 | <1% | 295 | $19K | |
| 87088 | <1% | 1,951 | $19K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,850 | $19K |
| 88108 | <1% | 309 | $18K | |
| 84100 | <1% | 4,522 | $18K | |
| 86923 | <1% | 728 | $18K | |
| 86850 | <1% | 1,644 | $18K | |
| 82248 | <1% | 3,381 | $18K | |
| 92582 | <1% | 589 | $18K | |
| 76377 | <1% | 841 | $17K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,054 | $17K |
| 94664 | <1% | 614 | $17K | |
| 82533 | <1% | 838 | $17K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 111 | $17K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,894 | $16K |
| V2756 | Eye glass case | <1% | 13,975 | $16K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 315 | $16K |
| 85610 | <1% | 3,128 | $16K | |
| 82397 | <1% | 934 | $16K | |
| 82977 | <1% | 2,124 | $16K | |
| 86376 | <1% | 985 | $15K | |
| 94150 | <1% | 127 | $15K | |
| 85046 | <1% | 2,704 | $14K | |
| 97803 | <1% | 795 | $14K | |
| 74455 | <1% | 61 | $14K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 435 | $14K |
| 77075 | <1% | 56 | $14K | |
| 84703 | <1% | 3,453 | $14K | |
| B4088 | Gastrostomy/jejunostomy tube, low-profile, any material, any type, each | <1% | 164 | $14K |
| 84403 | <1% | 735 | $14K | |
| 70210 | <1% | 120 | $13K | |
| 87430 | <1% | 770 | $13K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 483 | $13K |
| 82330 | <1% | 1,208 | $13K | |
| 97802 | <1% | 442 | $12K | |
| 87147 | <1% | 1,958 | $12K | |
| 80076 | <1% | 1,016 | $12K | |
| 70543 | <1% | 16 | $12K | |
| 87040 | <1% | 1,766 | $12K | |
| 36592 | <1% | 704 | $12K | |
| 92651 | <1% | 54 | $12K | |
| 87205 | <1% | 2,203 | $11K | |
| 93976 | <1% | 32 | $11K | |
| 83002 | <1% | 699 | $11K | |
| 84156 | <1% | 2,604 | $11K | |
| 94621 | <1% | 27 | $11K | |
| 83690 | <1% | 2,199 | $10K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 7,195 | $10K |
| A4217 | Sterile water/saline, 500 ml | <1% | 1,219 | $10K |
| 97166 | <1% | 69 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,098 | $10K |
| 83001 | <1% | 620 | $10K | |
| 86800 | <1% | 718 | $10K | |
| 82947 | <1% | 1,386 | $9K | |
| 82785 | <1% | 630 | $9K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 552 | $9K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $9K |
| 82610 | <1% | 539 | $8K | |
| 86902 | <1% | 584 | $8K | |
| 00635 | <1% | 28 | $8K | |
| 85651 | <1% | 1,860 | $8K | |
| 73110 | <1% | 78 | $8K | |
| 82043 | <1% | 1,300 | $8K | |
| 31526 | <1% | 12 | $8K | |
| 83605 | <1% | 1,497 | $7K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,806 | $7K |
| 83021 | <1% | 339 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 51 | $7K |
| 88304 | <1% | 211 | $7K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 318 | $7K |
| 80164 | <1% | 422 | $6K | |
| 82550 | <1% | 980 | $6K | |
| 86769 | <1% | 97 | $6K | |
| 80306 | <1% | 962 | $6K | |
| 80177 | <1% | 384 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 275 | $5K |
| 92586 | <1% | 13 | $5K | |
| 83993 | <1% | 294 | $5K | |
| 82150 | <1% | 884 | $5K | |
| 86592 | <1% | 293 | $5K | |
| 82310 | <1% | 912 | $5K | |
| 96401 | <1% | 610 | $5K | |
| 86901 | <1% | 1,582 | $5K | |
| 82670 | <1% | 185 | $4K | |
| 43760 | <1% | 14 | $4K | |
| 43762 | <1% | 12 | $4K | |
| 82657 | <1% | 116 | $4K | |
| 85730 | <1% | 1,314 | $4K | |
| 86355 | <1% | 99 | $4K | |
| 94645 | <1% | 44 | $4K | |
| 85014 | <1% | 1,765 | $4K | |
| 84270 | <1% | 254 | $4K | |
| 84402 | <1% | 260 | $4K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 737 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 931 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 294 | $4K |
| 82340 | <1% | 531 | $4K | |
| 83520 | <1% | 266 | $4K | |
| 86160 | <1% | 453 | $4K | |
| 94728 | <1% | 38 | $4K | |
| 90717 | <1% | 28 | $4K | |
| 93270 | <1% | 25 | $3K | |
| 73030 | <1% | 46 | $3K | |
| 87400 | <1% | 207 | $3K | |
| 89051 | <1% | 602 | $3K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 25 | $3K |
| 90691 | <1% | 63 | $3K | |
| 74430 | <1% | 16 | $3K | |
| 86038 | <1% | 195 | $3K | |
| 83020 | <1% | 156 | $3K | |
| 87529 | <1% | 70 | $3K | |
| 84295 | <1% | 511 | $3K | |
| 95700 | <1% | 14 | $3K | |
| 88300 | <1% | 146 | $2K | |
| 83615 | <1% | 622 | $2K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 301 | $2K |
| 94644 | <1% | 186 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 889 | $2K |
| 81025 | <1% | 877 | $2K | |
| 82607 | <1% | 107 | $2K | |
| 83498 | <1% | 101 | $2K | |
| 87328 | <1% | 137 | $2K | |
| 86359 | <1% | 86 | $2K | |
| 85240 | <1% | 78 | $2K | |
| 84132 | <1% | 413 | $2K | |
| 76010 | <1% | 70 | $2K | |
| 86317 | <1% | 69 | $2K | |
| 90734 | <1% | 14 | $2K | |
| 86665 | <1% | 180 | $2K | |
| 82962 | <1% | 1,841 | $2K | |
| 86357 | <1% | 70 | $2K | |
| 93786 | <1% | 14 | $2K | |
| 84145 | <1% | 715 | $2K | |
| 73620 | <1% | 16 | $2K | |
| 72100 | <1% | 26 | $1K | |
| 84484 | <1% | 360 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 25 | $1K |
| 85018 | <1% | 1,180 | $1K | |
| 87329 | <1% | 89 | $1K | |
| 86480 | <1% | 29 | $1K | |
| 87641 | <1% | 30 | $1K | |
| 29105 | <1% | 13 | $1K | |
| 86255 | <1% | 41 | $1K | |
| 81003 | <1% | 486 | $1K | |
| 88302 | <1% | 15 | $1K | |
| 84146 | <1% | 67 | $1K | |
| 86360 | <1% | 43 | $1K | |
| 80074 | <1% | 66 | $1K | |
| 80183 | <1% | 68 | $1K | |
| 86664 | <1% | 117 | $1K | |
| 87420 | <1% | 109 | $1K | |
| 86663 | <1% | 92 | $964.53 | |
| 87427 | <1% | 59 | $905.30 | |
| 87045 | <1% | 71 | $855.06 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 142 | $848.65 |
| 97116 | <1% | 17 | $845.65 | |
| 84550 | <1% | 245 | $834.04 | |
| 93788 | <1% | 14 | $828.94 | |
| 85378 | <1% | 429 | $806.80 | |
| 82024 | <1% | 14 | $781.55 | |
| 82652 | <1% | 30 | $776.05 | |
| L8613 | Ossicula implant | <1% | 77 | $723.72 |
| 82664 | <1% | 13 | $695.54 | |
| 87449 | <1% | 54 | $641.22 | |
| 80047 | <1% | 704 | $622.53 | |
| 82438 | <1% | 124 | $607.92 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 101 | $577.43 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 513 | $577.25 |
| 87046 | <1% | 46 | $559.10 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 114 | $503.53 |
| 73060 | <1% | 12 | $479.19 | |
| 86703 | <1% | 37 | $341.41 | |
| V2107 | Spherocylinder, single vision, plus or minus 4.25 to plus or minus 7.00 sphere, .12 to 2.00d cylinder, per lens | <1% | 13 | $339.04 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 713 | $333.89 |
| 80197 | <1% | 22 | $317.99 | |
| 86356 | <1% | 15 | $316.31 | |
| 84480 | <1% | 25 | $306.64 | |
| 86318 | <1% | 52 | $276.21 | |
| 80184 | <1% | 16 | $235.64 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 15 | $217.50 |
| 82390 | <1% | 14 | $210.73 | |
| 83525 | <1% | 15 | $205.17 | |
| 80175 | <1% | 13 | $198.59 | |
| 82085 | <1% | 15 | $194.04 | |
| 80349 | <1% | 55 | $173.74 | |
| 82565 | <1% | 74 | $150.32 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 126 | $147.50 |
| 82010 | <1% | 36 | $123.96 | |
| 86225 | <1% | 23 | $122.34 | |
| 70310 | <1% | 154 | $108.12 | |
| 80143 | <1% | 179 | $106.96 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,457 | $105.13 |
| 85660 | <1% | 13 | $87.68 | |
| 85347 | <1% | 20 | $43.73 | |
| 80179 | <1% | 122 | $40.34 | |
| 82435 | <1% | 29 | $8.94 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 526 | $0.00 |
| 82077 | 0% | 97 | $0.00 | |
| 2023F | 0% | 688 | $0.00 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 22 | $0.00 |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 340 | $0.00 |
| J7699 | Noc drugs, inhalation solution administered through dme | 0% | 69 | $0.00 |
| J2545 | Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg | 0% | 12 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 77 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 65 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 72 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 15 | $0.00 |
| J9260 | Injection, methotrexate sodium, 50 mg | 0% | 17 | $0.00 |
| 94799 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHACON, CHANDA (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Childrens Home Healthcare | Omaha, NE | $40.03M |
| Children's Hospital & Medical Center | Omaha, NE | $10.04M |
| Children's Home Healthcare | Omaha, NE | $502K |
| Childrens Hospital & Medical Center | Omaha, NE | $26K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.